Catalent

Tuesday, October 11, 2022 at 11am EDT | 10am CDT | 8am PDT Learn how integrated formulation and clinical manufacturing expertise, as well as strategic partnerships between CDMOs and CROs, can help achieve flexible and efficient first-in-human studies, fast development of challenging molecules, and reduced clinical development timelines and costs, all while increasing success rates.

Catalent’s global network of manufacturing and packaging facilities provide the capacity for efficient commercial supply of orphan, niche and low-volume drugs, which require agile, flexible and strategic solutions.

Catalent’s flexible global manufacturing network supports products throughout their lifecycle, from clinical to commercial supply.

Thursday, April 21, 2022 at 11am ET | 4pm GMT | 5pm CET This webinar will discuss risk mitigation strategies used to address common challenges during spray dried powder development and give insight into the impact of spray drying on powder properties in terms of manufacturability and downstream processability.

Biopharma 4.0 is fundamentally changing the way that manufacturers do business. It will enable better products produced faster, with consistent high quality at a reduced cost. The process of moving from silos of automated or semi-automated processes (Biopharma 3.0) to a fully connected enterprise comprised of smart things is a journey that many manufacturers are only just beginning. Tune in to learn more on the latest status and impact that Biopharma 4.0 has on biopharmaceutical manufacturing.

Catalent’s OptiDose Design Solution integrates pharmaceutics, critical CMC and DMPK parameters, and dose form design target patient characteristics to create differentiated treatments that are successful for innovators, patients and healthcare professionals.

The Boston, MA facility is Catalent’s global Center of Excellence for spray dry dispersion and Dry Powder Inhaler (DPI) capsule manufacture and packaging. The site has over 20 years of experience in inhalable dry powders and Catalent is the only CDMO globally to offer end-to-end spray drying, powder encapsulation and blister packaging capabilities from development through clinical and commercial manufacturing. This video tour showcases Catalent Boston’s manufacturing operations as well as on-site analytical support services.

There continues to be a rapid expansion in the orally inhaled therapeutic pipeline, underpinned by scientific, technological, manufacturing and regulatory advances across drug products and devices. In this Q&A article, Catalent experts Carolyn Berg and Carla Vozone discuss innovations in orally inhaled drug products, in particular dry powders for inhalation.

Thursday, February 24, 2022 at 11am EST| 8am PST| 4pm GMT|5pm CET This webinar will discuss the challenges, opportunities, and advantages of intranasal drug delivery and why it has drawn increasing interest as a route of administration. *** On demand available after final airing until November 18, 2022.***

One of the challenges facing gene therapy manufacturing is the lack of standardization in the process. Standardized methods, materials, analytics, and documentation can help reduce supply chain bottlenecks, increase efficiencies and lead to accelerated development timelines and smoother regulatory filings. In this podcast, we will discuss how Catalent is working to simplify the supply chain, develop processes scalable for late-stage and commercial needs, and accelerate timelines for production of clinical materials

Thursday, January 27th 2022 at 11AM EST | 4PM GMT | 8AM PST In this webinar, experts provide an overview of the needs of different patient populations, and examine the common challenges leading to non-compliance. The experts also discuss how an orally dissolving tablet (ODT) provides a solution to address patient challenges and enables potentially more successful treatments.

With more than 30 years’ experience, Catalent offers end-to-end solutions for multiple inhalation dose forms.

Catalent is a global leader in clinical supply services with flexible solutions for small molecules, biologics, and cell and gene therapies, including integrated services to accelerate products to the clinic.

Catalent’s OneXpress™ solution combines phase-appropriate scale and technologies with expertise across diverse dose forms to simplify development and accelerate a programme towards commercialisation.

*Wednesday, May 5, 2021 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST* What size API would work for an ODT targeting sublingual or enteric delivery? Why would one consider an ODT over a tablet or capsule for standard G.I. absorption? Learn more as Catalent discusses ODT technologies in this upcoming webinar. *On Demand Until May 5, 2022*

Catalent is the global leader in drug development and delivery, offering innovative development and manufacturing solutions for oral dosage forms.

**Tuesday, March 23, 2021, 1pm EDT | 10am PDT | 6pm GMT | 7pm CET*** Biopharmaceutical products in development continue to increase in complexity, which poses a challenge for pharmaceutical companies that are looking to improve speed and efficiency of biologic development. Join us for this webinar where we will discuss new cell line development methodologies, as well as new instrumentation, that are enabling these complex programs to be performed with shortened development timelines. *** On demand available after final airing until March 23, 2022.***

OptiForm® Total Supply integrates drug development, manufacturing, and clinical supply to streamline and accelerate projects

CTSuccess™ by Catalent employs proactive clinical supply risk evaluation and tailored strategies to ensure on-time start up and efficient material supply throughout clinical studies.

***Live: Tuesday, January 19, 2021, at 11am EST | 8am PST | 4pm GMT | 5pm CET ***Join this webcast to learn best practices to ensure a smooth transition from Phase 1 to Phase 2 studies, how a clinical supply provider can enable this process, as well as the role that integrated solutions can play***On demand available after final airing until Jan. 19, 2022***